"The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.
Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is"...
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Clinical Studies Experience
VECTICAL (calcitriol ointment) Ointment was studied in two vehicle-controlled studies (419 subjects), and in one open label study (324 subjects). The table below describes exposure to VECTICAL (calcitriol ointment) Ointment in 743 subjects, including 239 exposed for 6 months and 116 exposed for one year.
Four hundred and nineteen subjects were treated with VECTICAL (calcitriol ointment) Ointment twice daily for 8 weeks. The population included subjects ages 13 to 87, males (284) and females (135), Caucasians (372) and non-Caucasians (47); with mild (105) to moderate (313) chronic plaque psoriasis.
Selected Adverse Events Occurring in at least 1% of Subjects
in the Two Pooled Vehicle-Controlled Studies
Among subjects having laboratory monitoring, hypercalcemia was observed in 24% (18/74) of subjects exposed to active drug and in 16% (13/79) of subjects exposed to vehicle, however the elevations were less than 10% above the upper limit of normal [see WARNINGS AND PRECAUTIONS]
The open label study enrolled 324 subjects with psoriasis who were then treated for up to 52 weeks. Adverse events reported at a rate of greater than or equal to 3% of subjects treated with VECTICAL (calcitriol ointment) Ointment were lab test abnormality (8%), urine abnormality (4%), psoriasis (4%), hypercalciuria (3%), and pruritus (3%). Kidney stones were reported in 3 subjects and confirmed in two.
The following adverse reactions have been identified during world-wide post-approval use of VECTICAL (calcitriol ointment) Ointment: acute blistering dermatitis, erythema, pruritus, skin burning sensation, and skin discomfort. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the Vectical Ointment (calcitriol ointment) Side Effects Center for a complete guide to possible side effects
VECTICAL (calcitriol ointment) Ointment should be used with caution in patients receiving medications known to increase the serum calcium level, such as thiazide diuretics. Caution should also be exercised in patients receiving calcium supplements or high doses of vitamin D [see WARNINGS AND PRECAUTIONS].
Read the Vectical Ointment Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 3/10/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Vectical Ointment Information
Vectical Ointment - User Reviews
Vectical Ointment User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.